Tivicay contains the active ingredient dolutegravir, an integrase strand transfer inhibitor (INSTI) used as part of combination antiretroviral therapy (ART) for the treatment of HIV-1 infection. It is indicated for use in adults, adolescents, and eligible pediatric patients and is widely recommended in HIV treatment guidelines due to its potency, favorable resistance profile, and convenient dosing schedule.

Dolutegravir works by blocking the HIV integrase enzyme, which the virus requires to insert its genetic material into human cells and replicate. By inhibiting this process, Tivicay helps reduce the amount of HIV in the bloodstream (viral load), improve immune function, and decrease the risk of HIV-related complications when taken consistently as prescribed.

Tivicay is available as film-coated tablets in strengths of 10 mg, 25 mg, and 50 mg, as well as dispersible tablets for pediatric patients. Depending on the treatment regimen and patient characteristics, Tivicay is commonly taken once daily, although some patients may require twice-daily dosing based on resistance patterns or concomitant medications.

Clinical studies have demonstrated that Tivicay provides rapid and durable viral suppression, making it a cornerstone of many modern HIV treatment regimens. It is often used in combination with other antiretroviral agents to achieve and maintain an undetectable viral load.

Common side effects may include headache, insomnia, fatigue, nausea, diarrhea, and dizziness. Serious adverse reactions are uncommon but can include hypersensitivity reactions, liver problems, and immune reconstitution syndrome. Patients should discuss potential drug interactions and treatment considerations with their healthcare provider before starting therapy.